All In Biotech

Drug Trial Radar · NCT03975829

Pediatric Long-Term Follow-up and Rollover Study

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

163

Actual

Start

Nov 4, 2019

Primary completion

Nov 24, 2026

Study completion Nov 24, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Conditions

  • Diffuse Astrocytoma
  • Anaplastic Astrocytoma
  • Astrocytoma
  • Oligodendroglioma, Childhood
  • Anaplastic Oligodendroglioma
  • Glioblastoma
  • Pilocytic Astrocytoma
  • Giant Cell Astrocytoma
  • Pleomorphic Xanthoastrocytoma
  • Anaplastic Pleomorphic Xanthoastrocytoma
  • Angiocentric Glioma
  • Chordoid Glioma of Third Ventricle
  • Gangliocytoma
  • Ganglioglioma
  • Anaplastic Ganglioglioma
  • Dysplastic Gangliocytoma of Cerebrellum
  • Desmoplastic Infantile Astrocytoma and Ganglioglioma
  • Papillary Glioneuronal Tumor
  • Rosette-forming Glioneuronal Tumor
  • Central Neurocytoma
  • Extraventricular Neurocytoma
  • Cerebellar Liponeurocytoma
  • Neurofibromatosis Type 1

Interventions

  • dabrafenibDrug

    dabrafenib oral, twice daily

  • trametinibDrug

    trametinib oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events and Serious Adverse Events (SAEs)Time frame: Baseline up to approximately 7 years

Locations

54 sites in 19 countries. Site status is shown where the registry gives one.

  • Phoenix Children s Hospital

    Phoenix, Arizona

  • Childrens National Hospital

    Washington D.C., District of Columbia

  • Nicklaus Childrens Hospital

    Miami, Florida

  • Indiana Uni School of Medicine

    Indianapolis, Indiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Cinn Children Hosp Medical Center

    Cincinnati, Ohio

  • St Jude Childrens Research Hospital

    Memphis, Tennessee

  • Texas Childrens Hospital

    Houston, Texas

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Tampere, Finland, Finland

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Rennes, Brittany Region, France

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Petah Tikva, Israel

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.